title: Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment.
abstract: OBJECTIVE
  To longitudinally evaluate five cerebrospinal fluid (CSF) biomarkers in the transition from mild cognitive impairment (MCI) to Alzheimer's disease (AD).
  
  
  METHODS
  A baseline and 2-year follow-up clinical and CSF study of 86 subjects, including 22 MCI patients that declined to AD (MCI-AD), 43 MCI that did not deteriorate (MCI-MCI) and 21 controls (NL-NL). All subjects were studied for total and phosphorylated tau (T-tau, P-tau(231)), amyloid beta (Abeta) Abeta(42)/Abeta(40) ratio, isoprostane (IP) as well as P-tau(231)/Abeta(42/40) and T-tau/Abeta(42/40) ratios.
  
  
  RESULTS
  At baseline and at follow-up MCI-AD showed higher levels P-tau(231), T-tau, IP, P-tau(231)/Abeta(42/40) and T-tau/Abeta(42/40) ratios and lower Abeta(42)/Abeta(40) than MCI-MCI or NL-NL. Baseline P-tau(231) best predicted MCI-AD (80%, p<0.001) followed in accuracy by P-tau(231)/Abeta(42/40) and T-tau/Abeta(42/40) ratios (both 75%, p's<0.001), T-tau (74%, p<0.001), Abeta(42)/Abeta(40) (69%, p<0.01), and IP (68%, p<0.01). Only IP showed longitudinal effects (p<0.05).
  
  
  CONCLUSIONS
  P-tau(231) is the strongest predictor of the decline from MCI to AD. IP levels uniquely show longitudinal progression effects. These results suggest the use of CSF biomarkers in secondary prevention trials.
authors: New York University School of Medicine, NY, USA.
authors: Miroslaw
authors: M
authors: Brys
authors: Elizabeth
authors: E
authors: Pirraglia
authors: Kenneth
authors: K
authors: Rich
authors: Sindre
authors: S
authors: Rolstad
authors: Lisa
authors: L
authors: Mosconi
authors: Remigiusz
authors: R
authors: Switalski
authors: Lidia
authors: L
authors: Glodzik-Sobanska
authors: Susan
authors: S
authors: De Santi
authors: Ray
authors: R
authors: Zinkowski
authors: Pankaj
authors: P
authors: Mehta
authors: Domenico
authors: D
authors: Pratico
authors: Leslie A
authors: LA
authors: Saint Louis
authors: Anders
authors: A
authors: Wallin
authors: Kaj
authors: K
authors: Blennow
authors: Mony J
authors: MJ
authors: de Leon
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000134:cerebrospinal fluid* / Q000175:diagnosis*; D016229:Amyloid beta-Peptides / Q000032:analysis / Q000134:cerebrospinal fluid; D015415:Biomarkers / Q000032:analysis / Q000134:cerebrospinal fluid; D003072:Cognition Disorders / Q000134:cerebrospinal fluid* / Q000175:diagnosis*; D015331:Cohort Studies; D018450:Disease Progression; D042241:Early Diagnosis; D005260:Female; D006801:Humans; D028421:Isoprostanes / Q000032:analysis / Q000134:cerebrospinal fluid; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D010446:Peptide Fragments / Q000032:analysis / Q000134:cerebrospinal fluid; D011237:Predictive Value of Tests; D011379:Prognosis; D016875:tau Proteins / Q000032:analysis / Q000134:cerebrospinal fluid*
chemical_list: D016229:Amyloid beta-Peptides; D015415:Biomarkers; D028421:Isoprostanes; D010446:Peptide Fragments; C078592:amyloid beta-protein (1-40); C075222:amyloid beta-protein (1-42); D016875:tau Proteins